<p>Tandem Diabetes Care, Inc.（納斯達克代碼：TNDM - 獲取免費報告）在週五的交易中下跌了 6.2%。該公司的股價最低曾達到 20.07 美元，最後交易價為 19.96 美元。交易期間大約交易了 558,807 股，較日均交易量 1,487,655 股下降了 62%。該股票之前的收盤價為 21.28 美元。</p>
<p>獲取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>幾位股票研究分析師對 TNDM 股票發佈了報告。Piper Sandler 將 Tandem Diabetes Care 的股票目標價從 36.00 美元下調至 30.00 美元，並在 5 月 1 日的研究報告中給予該公司 “增持” 評級。Canaccord Genuity Group 將 Tandem Diabetes Care 的股票目標價從 58.00 美元上調至 59.00 美元，並在 5 月 1 日的研究報告中給予該股票 “買入” 評級。Mizuho 在 4 月 10 日的研究報告中開始覆蓋 Tandem Diabetes Care 的股票。他們給予該公司 “中性” 評級，目標價為 20.00 美元。Sanford C. Bernstein 將 Tandem Diabetes Care 的股票評級從 “跑贏大盤” 下調至 “市場表現”，並在 2 月 28 日的研究報告中將該公司的目標價從 35.00 美元下調至 25.00 美元。最後，摩根士丹利在 3 月 3 日的研究報告中將 Tandem Diabetes Care 的目標價從 42.00 美元下調至 24.00 美元，並給予該公司 “中性” 評級。八位投資分析師對該股票給予了持有評級，八位分析師則給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 37.47 美元。</p>
<p><strong>查看我們對 Tandem Diabetes Care 的最新分析</strong></p>
<h2>Tandem Diabetes Care 下跌 6.3%</h2>
<p>該公司的市值為 13.3 億美元，市盈率為-10.28，貝塔值為 1.47。該公司的債務與股本比率為 1.29，速動比率為 2.32，流動比率為 2.90。該公司的 50 日簡單移動平均線為 19.44 美元，200 日簡單移動平均線為 27.20 美元。</p>
<p>Tandem Diabetes Care（納斯達克代碼：TNDM - 獲取免費報告）最近一次發佈財報是在 4 月 30 日，醫療設備公司報告本季度每股收益為（0.67 美元），低於分析師的共識預期（0.60 美元）0.07 美元。該公司本季度的收入為 2.3442 億美元，而分析師的預期為 2.2019 億美元。Tandem Diabetes Care 的淨利潤率為-14.84%，股本回報率為-44.19%。該公司的季度收入較去年同期增長了 22.3%。在去年同期，該公司每股收益為（0.65 美元）。股票研究分析師預測 Tandem Diabetes Care, Inc.在本年度的每股收益將為-1.68 美元。</p>
<h2>Tandem Diabetes Care 的內部買賣情況</h2>
<p>在相關消息中，首席運營官 Jean-Claude Kyrillos 在 3 月 7 日（星期五）以每股 18.12 美元的平均價格購買了 10,538 股該股票，總交易額為 190,948.56 美元。購買後，首席運營官現在擁有 10,538 股公司股票，價值約為 190,948.56 美元。此次交易使他們的持股增加了∞。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接訪問。內部人士持有公司 1.90% 的股份。</p>
<h2>機構投資者對 Tandem Diabetes Care 的看法</h2>
<p>一些機構投資者最近增加或減少了在 TNDM 的持股。AlphaQuest LLC 在第四季度將其在 Tandem Diabetes Care 的持股增加了 138.7%。AlphaQuest LLC 現在擁有 931 股醫療設備公司的股票，價值 34,000 美元，此前在上個季度又購買了 541 股。Assetmark Inc.在第一季度將其在 Tandem Diabetes Care 的持股增加了 42.9%。Assetmark Inc.現在擁有 1,750 股醫療設備公司的股票，價值 34,000 美元，此前在此期間又購買了 525 股。NBC Securities Inc.在第一季度購買了 Tandem Diabetes Care 的新股份，價值約為 37,000 美元。Jones Financial Companies Lllp 在第四季度將其在 Tandem Diabetes Care 的持股增加了 195.8%。Jones Financial Companies Lllp 現在擁有 1,130 股醫療設備公司的股票，價值 41,000 美元，此前在上個季度又購買了 748 股。最後，Smartleaf Asset Management LLC 在第四季度將其在 Tandem Diabetes Care 的持股增加了 163.4%。Smartleaf Asset Management LLC 現在擁有 1,775 股醫療設備公司的股票，價值 65,000 美元，此前在上個季度又購買了 1,101 股。</p>
<h2>Tandem Diabetes Care 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Tandem Diabetes Care, Inc.是一家醫療設備公司，設計、開發並商業化技術解決方案，服務於美國及國際上生活在糖尿病中的人羣。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送的平台，並能在泵的主屏幕上直接顯示連續血糖監測傳感器信息；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Tandem Diabetes Care</li>
<li>10 只最佳航空公司股票推薦</li>
<li>Nike 在亞馬遜的擴張可能預示着 2025 年的轉機</li>
<li>3 只前景良好的金融科技股票</li>
<li>英特爾的轉機可能是無人關注的最佳投資</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>3 只將從金色圓頂中獲利的防禦類股票</li>
</ul>
<p><em>這條即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Tandem Diabetes Care 嗎？</h2>
<p>在你考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Tandem Diabetes Care 並不在名單上。</p>
<p>雖然 Tandem Diabetes Care 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TNDM

<p>Tandem Diabetes Care（納斯達克代碼：TNDM）股價下跌 6.2%，至 19.96 美元，交易量較平均水平下降 62%。分析師們調整了目標價格，Piper Sandler 將其下調至 30.00 美元，而 Canaccord Genuity 則將其上調至 59.00 美元。該公司報告季度每股虧損 0.67 美元，未能達到預期，但收入同比增長 22.3%。內部人士的買入行為被注意到，機構投資者也在調整其在公司的持股。該股票的共識評級為 “適度買入”，目標價格為 37.47 美元</p>

<p>Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) was down 6.2% during trading on Friday . The company traded as low as $20.07 and last traded at $19.96. Approximately 558,807 shares were traded during trading, a decline of 62% from the average daily volume of 1,487,655 shares. The stock had previously closed at $21.28.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.（納斯達克代碼：TNDM - 獲取免費報告）在週五的交易中下跌了 6.2%。該公司的股價最低曾達到 20.07 美元，最後交易價為 19.96 美元。交易期間大約交易了 558,807 股，較日均交易量 1,487,655 股下降了 62%。該股票之前的收盤價為 21.28 美元。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>Several equities research analysts have issued reports on TNDM shares. Piper Sandler decreased their price objective on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, May 1st. Canaccord Genuity Group upped their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, May 1st. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They issued a &#34;neutral&#34; rating and a $20.00 target price for the company. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and decreased their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their target price on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a &#34;neutral&#34; rating for the company in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $37.47.</p>
<div class="lb-trans"><p>幾位股票研究分析師對 TNDM 股票發佈了報告。Piper Sandler 將 Tandem Diabetes Care 的股票目標價從 36.00 美元下調至 30.00 美元，並在 5 月 1 日的研究報告中給予該公司 “增持” 評級。Canaccord Genuity Group 將 Tandem Diabetes Care 的股票目標價從 58.00 美元上調至 59.00 美元，並在 5 月 1 日的研究報告中給予該股票 “買入” 評級。Mizuho 在 4 月 10 日的研究報告中開始覆蓋 Tandem Diabetes Care 的股票。他們給予該公司 “中性” 評級，目標價為 20.00 美元。Sanford C. Bernstein 將 Tandem Diabetes Care 的股票評級從 “跑贏大盤” 下調至 “市場表現”，並在 2 月 28 日的研究報告中將該公司的目標價從 35.00 美元下調至 25.00 美元。最後，摩根士丹利在 3 月 3 日的研究報告中將 Tandem Diabetes Care 的目標價從 42.00 美元下調至 24.00 美元，並給予該公司 “中性” 評級。八位投資分析師對該股票給予了持有評級，八位分析師則給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 37.47 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Tandem Diabetes Care 的最新分析</strong></p>
</div><h2>Tandem Diabetes Care Trading Down 6.3%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 下跌 6.3%</h2>
</div><p>The firm has a market capitalization of $1.33 billion, a P/E ratio of -10.28 and a beta of 1.47. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The firm has a 50 day simple moving average of $19.44 and a two-hundred day simple moving average of $27.20.</p>
<div class="lb-trans"><p>該公司的市值為 13.3 億美元，市盈率為-10.28，貝塔值為 1.47。該公司的債務與股本比率為 1.29，速動比率為 2.32，流動比率為 2.90。該公司的 50 日簡單移動平均線為 19.44 美元，200 日簡單移動平均線為 27.20 美元。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.65) EPS. Equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（納斯達克代碼：TNDM - 獲取免費報告）最近一次發佈財報是在 4 月 30 日，醫療設備公司報告本季度每股收益為（0.67 美元），低於分析師的共識預期（0.60 美元）0.07 美元。該公司本季度的收入為 2.3442 億美元，而分析師的預期為 2.2019 億美元。Tandem Diabetes Care 的淨利潤率為-14.84%，股本回報率為-44.19%。該公司的季度收入較去年同期增長了 22.3%。在去年同期，該公司每股收益為（0.65 美元）。股票研究分析師預測 Tandem Diabetes Care, Inc.在本年度的每股收益將為-1.68 美元。</p>
</div><h2>Insider Buying and Selling at Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 的內部買賣情況</h2>
</div><p>In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Insiders own 1.90% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席運營官 Jean-Claude Kyrillos 在 3 月 7 日（星期五）以每股 18.12 美元的平均價格購買了 10,538 股該股票，總交易額為 190,948.56 美元。購買後，首席運營官現在擁有 10,538 股公司股票，價值約為 190,948.56 美元。此次交易使他們的持股增加了∞。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接訪問。內部人士持有公司 1.90% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>機構投資者對 Tandem Diabetes Care 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in TNDM. AlphaQuest LLC raised its holdings in shares of Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Assetmark Inc. raised its stake in shares of Tandem Diabetes Care by 42.9% during the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after buying an additional 525 shares during the period. NBC Securities Inc. purchased a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $37,000. Jones Financial Companies Lllp increased its position in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after purchasing an additional 748 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after buying an additional 1,101 shares in the last quarter.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了在 TNDM 的持股。AlphaQuest LLC 在第四季度將其在 Tandem Diabetes Care 的持股增加了 138.7%。AlphaQuest LLC 現在擁有 931 股醫療設備公司的股票，價值 34,000 美元，此前在上個季度又購買了 541 股。Assetmark Inc.在第一季度將其在 Tandem Diabetes Care 的持股增加了 42.9%。Assetmark Inc.現在擁有 1,750 股醫療設備公司的股票，價值 34,000 美元，此前在此期間又購買了 525 股。NBC Securities Inc.在第一季度購買了 Tandem Diabetes Care 的新股份，價值約為 37,000 美元。Jones Financial Companies Lllp 在第四季度將其在 Tandem Diabetes Care 的持股增加了 195.8%。Jones Financial Companies Lllp 現在擁有 1,130 股醫療設備公司的股票，價值 41,000 美元，此前在上個季度又購買了 748 股。最後，Smartleaf Asset Management LLC 在第四季度將其在 Tandem Diabetes Care 的持股增加了 163.4%。Smartleaf Asset Management LLC 現在擁有 1,775 股醫療設備公司的股票，價值 65,000 美元，此前在上個季度又購買了 1,101 股。</p>
</div><h2>Tandem Diabetes Care Company Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.是一家醫療設備公司，設計、開發並商業化技術解決方案，服務於美國及國際上生活在糖尿病中的人羣。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送的平台，並能在泵的主屏幕上直接顯示連續血糖監測傳感器信息；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Nike’s Amazon Expansion Could Signal a Turnaround in 2025</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Tandem Diabetes Care</li>
<li>10 只最佳航空公司股票推薦</li>
<li>Nike 在亞馬遜的擴張可能預示着 2025 年的轉機</li>
<li>3 只前景良好的金融科技股票</li>
<li>英特爾的轉機可能是無人關注的最佳投資</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>3 只將從金色圓頂中獲利的防禦類股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這條即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tandem Diabetes Care 嗎？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Tandem Diabetes Care 並不在名單上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tandem Diabetes Care 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tandem Diabetes Care（NASDAQ:TNDM）股價下跌 6.2% - 現在是否應該賣出？